• Received US$185,000 order from Serum Institute of India
• Evaluating new AnteoTech prototype product for ELISA development
• New AnteoBindTM sales secured with Japanese customers

AnteoTech Ltd (ASX: ADO) has provided an update on progress within its Life Sciences business. Key highlights include:- Received a US$185,000 (~AU$275,750) order for AnteoBindTM from the Serum Institute of India (SII), with dispatch to take place on 5th January 2026.- SII has agreed to evaluate a new AnteoTech prototype product for use in plate-based ELISA development.- New AnteoBindTM sales secured with Japanese customers (~AU$70,000).- Sales pipeline growth continues, with 10 new AnteoBind NXT evaluations initiated since September 2025 across Europe, North America, India and Asia.- Progress made re-engaging with large global life sciences companies, with interest in joint development, commercialisation and direct product supply.- Discussions underway for the first phase of a joint CLIA product development program incorporating AnteoBindTM NXT.- Comparative studies indicate AnteoBindTM NXT delivers significant performance and cost benefits versus Tosyl chemistry in CLIA development.- New Life Sciences products under development expected to see AnteoBindTM transition from an additive to a core ingredient.- Three peer-reviewed publications highlighted the advantages of AnteoBindTM across immunoassay and diagnostic applications.

The company expects further sales to SII this financial year. The ELISA market segment represents approximately 40% of the global immunoassays market, valued at US$21 billion and forecast to grow at 5% CAGR through to 2029. The CLIA market is estimated to have a value of US$13 billion and is forecast to grow at around 6% CAGR through to 2029.

AnteoTech is well positioned to secure new sales opportunities and to deliver increasing strategic value as the company moves into 2026. The Life Sciences business unit is expected to continue making solid progress.